#ASH18: Allogene ticks off a high CR rate for updated off-the-shelf CAR-T pioneer. But getting just the right kind of immunosuppression is crucial
So far this year Allogene has barreled out of left field with a pair of the most experienced CAR-T execs in the industry steering the new business to a record-setting (for now) IPO. And they’re headed straight into their first update on data for what an off-the-shelf CAR-T can do for patients suffering from acute lymphoblastic leukemia — with what they believe is a manageable safety profile.
Still tinkering with what they envision is just the right kind of edited CAR-T for the work, their UCART19 program — picked up from Pfizer and partnered with Cellectis — produced some promising proof-of-concept results on the first 21 patient results pooled from two small studies. Fourteen out of 17 pre-treated with a standard flu/cy lymphodepletion regimen plus an immunosuppressing therapy achieved a complete response with significant cell expansion.
Basic subscription required
Unlock this story instantly and join 57,400+ biopharma pros reading Endpoints daily — and it's free.